熱門資訊> 正文
韦德布什（Wedbush）以Outperate发起，Tourism Bio崛起
2025-03-07 03:39
- Tourmaline Bio (NASDAQ:TRML) has been initiated at Wedbush with Outperform rating as it believes the compay's heart disease treatment has potential.
- The company's stock is up about 10%.
- Wedbush said that with inflammation remaining largely unaddressed in atheroscleroticcardiovascular disease, "Prior CANTOS study showed an anti-inflammatory therapy can reduce the risk of a cardiovascular event, which makes us positive on the setup for TRML's pacibekitug."
- Wedbush has a PT of $42 for the company and estimates earliest potential pacibekitug market entry in late 2028 and peak revenue reaching >$1B.
More on Talaris Therapeutics
- Seeking Alpha’s Quant Rating on Talaris Therapeutics
- Historical earnings data for Talaris Therapeutics
- Financial information for Talaris Therapeutics
推薦文章
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
美股機會日報 | 6月零售數據高於市場預期；臺積電績后漲超3%
美股「七巨頭」迎特朗普關稅后首次大考！Q2能否交出亮眼成績單，繼續引領美股上漲？
華盛早報丨TACO交易再現！特朗普閃電改口「解僱鮑威爾」；美國眾議院加密貨幣立法進程受阻
財報前瞻 | 特斯拉Q2營收料下滑10%！股價銷量雙殺下，馬斯克能否逆轉局勢？
美股機會日報 | 低於市場預期！美國6月PPI同比增長2.3%；特斯拉官宣Model Y L
華盛早報丨事關中美關税！美財長最新放風；「加密周」突發！多項加密貨幣法案遭眾議院否決
美股機會日報 | 6月CPI符合預期！英偉達盤前漲超4%，今夜有望再創新高
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
